JosephDavidMeserveMD

Hospital Medicine/Hospitalist

Physician

Dr. Meserve is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3 Richland Medical Park Dr
Ste 120
Columbia, SC 29203
Phone+1 803-434-8866

Fax+1 803-933-3049

University of California (San Diego) Medical CenterResidency, Internal Medicine, 2015 - 2018
Medical University of South CarolinaClass of 2015

PubMed

Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn's Disease: A Multicenter Study.
Jeffrey D McCurdy, Javeria Munir, Simon Parlow, Jacqueline Reid, Russell Yanofsky
Clinical Gastroenterology and Hepatology. 2024-05-01
5 citations
Temporary Faecal Diversion for Refractory Perianal and/or Distal Colonic Crohn's Disease in the Biologic Era: An Updated Systematic Review with Meta-analysis.
Michael Jew, Joseph Meserve, Samuel Eisenstein, Vipul Jairath, Jeffrey McCurdy
Journal of Crohn's & Colitis. 2024-03-01
Editorial: risk of pneumonia in IBD-reading between the lines!
Joseph Meserve, Siddharth Singh
Alimentary Pharmacology & Therapeutics. 2021-12-01

Journal Articles

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Leah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Gursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature